Genesys Capital

Genesys Capital, founded in 2000 and based in Toronto, is a leading venture capital firm specializing in early-stage life sciences investments. The firm focuses on high-potential companies in sectors such as biotechnology, medical devices, and pharmaceuticals, aiming to support innovations that significantly improve health outcomes. Genesys Capital has successfully raised over $300 million and invested $250 million across 38 companies, achieving 18 exits. Notable investments include Fusion Pharmaceuticals, a clinical-stage oncology company, and Profound Medical, which develops MRI-guided ultrasound devices for incision-free therapies. The firm emphasizes a hands-on approach, providing strategic guidance and leveraging its extensive network to support the growth of its portfolio companies. The Genesys team, led by experienced professionals such as CEO Mark Vincent, combines deep scientific expertise with business acumen. The firm’s investment strategy is characterized by a commitment to fostering innovation and advancing groundbreaking technologies in the life sciences sector.